Nanotechnology-Based Precision Tools for the Detection and Treatment of Cancer

Mirkin is the George B. Rathmann Professor of Chemistry and the Director of the Institute for Nanotechnology and the Center for Nanofabrication and Molecular Self-Assembly at Northwestern University in Evanston.Professor Mirkin holds a B.S. degree from Dickinson College (1986) and a Ph.D. degree in chemistry from The Pennsylvania State University (1989). He was a NSF Postdoctoral Fellow at the Massachusetts Institute of Technology before becoming a chemistry professor at Northwestern University in 1991.Professor Mirkin is known for his development of nanoparticle-based biodetection schemes and his invention of Dip-Pen Nanolithography. He is the founder of two companies, Nanosphere and NanoInk, which are commercializing nanotechnology applications in the life science and semiconductor industries.Professor Mirkin has been recognized for his accomplishments with the 2004 Nobel Laureate Signature Award for Graduate Education in Chemistry (2003), the 2003 Raymond and Beverly Sackler Prize in the Physical Sciences, the 2002 Feynman Prize in Nanotechnology, the 2001 Leo Hendrick Baekeland Award, the Discover 2000 Award for Technological Innovation, I-Street Magazine's Top 5 List for Leading Academics in Technology, the Materials Research Society Young Investigator Award (2000), the ACS Award in Pure Chemistry (1999), the PLU Fresenius Award (1998), the Harvard University E. Bright Wilson Prize (1998), and the BF Goodrich Collegiate Inventors Award (1997).

Nanoflares as Probes for Cancer Diagnostics.- Therapeutic Applications of Spherical Nucleic Acids.- Theranostic Magnetic Nanostructures (MNS) for Cancer.- Nanodiamond-Based Chemotherapy and Imaging.- Theranostic Lipid Nanoparticles for Cancer Medicine.- Synthetic High-Density Lipoprotein-Like Nanoparticles as Cancer Therapy.- Radiosensitization and Nanoparticles.- Hybrid Nanoparticles for Cancer Imaging and Therapy.- Exploring Tumor Microenvironment with Nanoparticles.- How nanoparticles interact with cancer cells.- Engineering the Nanoparticle-Protein Interface for Cancer Therapeutics.- Calibration-Quality Cancer Nano-Therapeutics.- Cancer Nano-Therapeutics in Clinical Trials.